Key Dates

Related Announcements

• September 22, 2022 - Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional). See NOFO RFA-HG-22-027.  

Issued by

National Human Genome Research Institute (NHGRI)

Purpose

The R&R Budget Form for RFA-HG-22-027 incorrectly supports 5 budget periods, which is corrected by this Notice to allow 7 budget periods.

The application forms package originally posted with RFA-HG-22-027 mistakenly included an R&R Budget form which only supports 5 budget periods. However, the announcement states, “The UG3 phase is 1 - 3 years. The UH3 phase is 4-5 years depending on the length of the UG3 phase. The maximum period of funding for the entire UG3/UH3 application is seven years.”; the total project period may not exceed from one to three years for the UG3 phase and four to five years for the UH3 phase depending on the length of the UGH3 phase. The maximum period of funding for the entire UG3/UH3 application is seven years.”

To address this issue, a new application forms package which can accommodate all the budget periods has been posted in Grants.gov identified by FORMS-H-REVISED. If you initiated an application using the original (FORMS-H) package, you must move the application information to the FORMS-REVISED application package to successfully submit. If you are not sure which application package you are using, check out this resource.

Note: ASSIST, Workspace and many institutional system-to-system solutions allow application data to be easily copied from one application package to another. In this case, the “copy” feature will move all but your budget data to the --new form package. Contact appropriate support team for assistance (ASSIST – eRA Service Desk; Workspace – Grants.gov Contact Center).

Inquiries

Please direct all inquiries to:

Ebony Madden, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-503-5620
Email: ebony.madden@nih.gov